Literature DB >> 3872406

In vitro susceptibilities of Haemophilus influenzae isolates from a Veterans Administration Medical Center.

D J Flournoy.   

Abstract

One hundred and one consecutively occurring clinical isolates of H. influenzae, from adult male patients, were tested for quantitative antimicrobial susceptibility (by broth microdilution) and classification properties. Almost all were susceptible to a variety of antimicrobials, except erythromycin and ampicillin; 14% were ampicillin resistant. Beta-lactamase was produced by all the ampicillin-resistant strains. Most isolates were biotype II (68%) or III (24%). Only 6% were serotype b, while 94% were from the lower respiratory tract. When isolates were grouped according to biotype, serotype, B-lactamase production and site of isolation, there were some significant differences in susceptibilities among the groups.

Entities:  

Mesh:

Year:  1985        PMID: 3872406     DOI: 10.1007/bf02125034

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  9 in total

1.  Biochemical characteristics of Haemophilus influenzae in relationship to source of isolation and antibiotic resistance.

Authors:  W L Albritton; S Penner; L Slaney; J Brunton
Journal:  J Clin Microbiol       Date:  1978-06       Impact factor: 5.948

2.  Susceptibility studies of multiply resistant Haemophilus influenzae isolated from pediatric patients and contacts.

Authors:  J Campos; S Garcia-Tornel; I Sanfeliu
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

3.  Nontuberculous mycobacterial trends at the Veterans Administration Medical Center in Oklahoma City.

Authors:  P P Omondi; D J Flournoy; N R Asal; D E Parker; A W Nunnery
Journal:  South Med J       Date:  1983-01       Impact factor: 0.954

4.  Common beta-lactamase-specifying plasmid in Haemophilus ducreyi and Neisseria gonorrhoeae.

Authors:  B Anderson; W L Albritton; J Biddle; S R Johnson
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b.

Authors:  Y Sakata; G H McCracken; M L Thomas; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

6.  Mechanism of resistance of an ampicillin-resistant, beta-lactamase-negative clinical isolate of Haemophilus influenzae type b to beta-lactam antibiotics.

Authors:  T R Parr; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

7.  Detection of beta lactamase producing bacteria by Cefinase: comparison with three other methods.

Authors:  S M Qadri; F Perryman; D J Flournoy; M I de Silva
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1983-11

8.  Rapid biochemical characterization of Haemophilus species by using the micro-ID.

Authors:  S C Edberg; E Melton; J M Singer
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

9.  Distribution and relationship to serotype of Haemophilus influenzae biotypes isolated from upper respiratory tracts of children and adults in Papua New Guinea.

Authors:  M Gratten; T Lupiwa; J Montgomery; G Gerega
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

  9 in total
  3 in total

1.  Length of hospital stay in surgical service patients with nosocomial Hemophilus influenzae infections.

Authors:  D J Flournoy; L Hall; G Klein; L N Slater
Journal:  J Natl Med Assoc       Date:  1989-01       Impact factor: 1.798

2.  The relationship of organism pathogenicity and route of acquisition to antimicrobial susceptibilities.

Authors:  D J Flournoy; C K Murray
Journal:  J Natl Med Assoc       Date:  1993-06       Impact factor: 1.798

3.  Profile of patients from a Veterans Administration medical center.

Authors:  D J Flournoy; L Adkins
Journal:  J Natl Med Assoc       Date:  1988-05       Impact factor: 1.798

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.